These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32627277)

  • 1. Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
    Lewis RA; Cornblath DR; Hartung HP; Sobue G; Lawo JP; Mielke O; Durn BL; Bril V; Merkies ISJ; Bassett P; Cleasby A; van Schaik IN;
    J Peripher Nerv Syst; 2020 Sep; 25(3):230-237. PubMed ID: 32627277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
    Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
    J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ;
    Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgPro20, the Polyneuropathy and Treatment with Hizentra
    Berger M; Harbo T; Cornblath DR; Mielke O
    Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
    Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR;
    J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Alcantara M; Hartung HP; Lawo JP; Durn BL; Mielke O; Bril V
    Clin Neurophysiol; 2021 Sep; 132(9):2184-2190. PubMed ID: 34293528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
    Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
    Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study.
    Bril V; Hartung HP; Lawo JP; Durn BL; Mielke O
    Clin Neurophysiol; 2021 Jan; 132(1):226-231. PubMed ID: 33039291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
    van Schaik IN; Mielke O; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Durn BL; Cornblath DR; Merkies ISJ;
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e590. PubMed ID: 31355323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
    Tortorici MA; Yuraszeck T; Cornblath D; Bril V; Hartung HP; Sobue G; Lewis RA; Merkies ISJ; Lawo JP; Praus M; Durn BL; Mielke O; Ma X; Jauslin P; Pfister M; van Schaik IN;
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):839-850. PubMed ID: 34085779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
    Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Globulin Subcutaneous (Human) 20% (Hizentra
    Lamb YN; Syed YY; Dhillon S
    CNS Drugs; 2019 Aug; 33(8):831-838. PubMed ID: 31347096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials.
    Zis P; Hadjivassiliou M; Sarrigiannis PG; Jenkins TM; Mitsikostas DD
    J Neurol Sci; 2018 May; 388():79-83. PubMed ID: 29627036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2013 Jun; (6):CD003280. PubMed ID: 23771584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
    Hughes RA
    Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.